{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:44:40Z","timestamp":1777121080584,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:00:00Z","timestamp":1369872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0062-y","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T07:36:25Z","timestamp":1369812985000},"page":"845-855","source":"Crossref","is-referenced-by-count":28,"title":["S-1 (Teysuno\u00ae): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations"],"prefix":"10.1007","volume":"73","author":[{"given":"M.","family":"Sanford","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,5,30]]},"reference":[{"issue":"1","key":"62_CR1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CMAR.S12713","volume":"3","author":"T Delaunoit","year":"2011","unstructured":"Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3(1):257\u201366.","journal-title":"Cancer Manag Res"},{"key":"62_CR2","doi-asserted-by":"crossref","unstructured":"Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5(Suppl1):5\u201311.","DOI":"10.1007\/s10120-002-0203-6"},{"key":"62_CR3","unstructured":"International Agency for Research on Cancer. Stomach cancer incidence and mortality worldwide in 2008. http:\/\/globocan.iarc.fr\/factsheets\/cancers\/stomach.asp . Accessed 18 December 2012."},{"issue":"18","key":"62_CR4","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"62_CR5","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2012.709234","volume":"13","author":"T Satoh","year":"2012","unstructured":"Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother. 2012;13(13):1943\u201359.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 5","key":"62_CR6","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdq164","volume":"21","author":"A Okines","year":"2010","unstructured":"Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v50\u20134.","journal-title":"Ann Oncol"},{"issue":"2","key":"62_CR7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer. 2011;14(2):113\u201323.","journal-title":"Gastric Cancer"},{"key":"62_CR8","unstructured":"European Medicines Agency. Teysuno 15\u00a0mg\/4.35\u00a0mg\/11.8\u00a0mg hard capsules: summary of product characteristics. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001242\/WC500104415.pdf . Accessed 11 April 2013."},{"issue":"3","key":"62_CR9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425247.2012.652945","volume":"9","author":"K Miura","year":"2012","unstructured":"Miura K, Shirasaka T, Yamaue H, et al. S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv. 2012;9(3):273\u201386.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"62_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-007-0440-9","volume":"10","author":"Y Sakurai","year":"2007","unstructured":"Sakurai Y, Kamoshida S, Furuta S, et al. Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric Cancer. 2007;10(4):234\u201340.","journal-title":"Gastric Cancer"},{"key":"62_CR11","doi-asserted-by":"crossref","unstructured":"Kang YK. Phase I\/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer. Gastric Cancer. 2009;12(Suppl1):38\u201342.","DOI":"10.1007\/s10120-008-0472-9"},{"issue":"9","key":"62_CR12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0959-8049(03)00237-5","volume":"39","author":"P Chollet","year":"2003","unstructured":"Chollet P, Sch\u00f6ffski P, Weigang-K\u00f6hler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer. 2003;39(9):1264\u201370.","journal-title":"Eur J Cancer"},{"issue":"2","key":"62_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000331010","volume":"81","author":"KY Chung","year":"2011","unstructured":"Chung KY, Saito K, Zergebel C, et al. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011;81(2):65\u201372.","journal-title":"Oncology"},{"issue":"28","key":"62_CR14","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1200\/JCO.2005.01.917","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005;23(28):6957\u201365.","journal-title":"J Clin Oncol"},{"issue":"1","key":"62_CR15","first-page":"134","volume":"9","author":"PM Hoff","year":"2003","unstructured":"Hoff PM, Saad ED, Ajani JA, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28\u00a0days in patients with solid tumors. Clin Cancer Res. 2003;9(1):134\u201342.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"62_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-006-0265-y","volume":"59","author":"AX Zhu","year":"2007","unstructured":"Zhu AX, Clark JW, Ryan DP, et al. Phase I and pharmacokinetic study of S-1 administered for 14\u00a0days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007;59(3):285\u201393.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"62_CR17","first-page":"34","volume":"30","author":"N Sugimoto","year":"2012","unstructured":"Sugimoto N, Tanaka J, Tsuda M, et al. A phase II study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1) [abstract no. 70]. J Clin Oncol. 2012;30(Suppl):34.","journal-title":"J Clin Oncol"},{"issue":"4","key":"62_CR18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s12032-010-9590-4","volume":"28","author":"IS Choi","year":"2011","unstructured":"Choi IS, Lee HS, Lee K-W, et al. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28(4):991\u20138.","journal-title":"Med Oncol"},{"issue":"36","key":"62_CR19","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3748\/wjg.v16.i36.4575","volume":"16","author":"I Miyazaki","year":"2010","unstructured":"Miyazaki I, Kawai T, Harada Y, et al. A predictive factor for the response to S-1 plus cisplatin in gastric cancer. World J Gastroenterol. 2010;16(36):4575\u201382.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"62_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ijc.24726","volume":"126","author":"W Koizumi","year":"2010","unstructured":"Koizumi W, Tanabe S, Azuma M, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010;126(1):162\u201370.","journal-title":"Int J Cancer"},{"issue":"7","key":"62_CR21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jjco\/hym057","volume":"37","author":"N Boku","year":"2007","unstructured":"Boku N, Ohtsu A, Nagashima F, et al. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. Jpn J Clin Oncol. 2007;37(7):509\u201314.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"62_CR22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00280-012-1964-1","volume":"70","author":"BW Kang","year":"2012","unstructured":"Kang BW, Jeong JY, Chae YS, et al. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2012;70(5):735\u201341.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"62_CR23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2011.24","volume":"104","author":"SR Park","year":"2011","unstructured":"Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011;104(7):1126\u201334.","journal-title":"Br J Cancer"},{"issue":"2","key":"62_CR24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bjc.2012.572","volume":"108","author":"A Sekikawa","year":"2013","unstructured":"Sekikawa A, Fukui H, Zhang X, et al. REG 1\u03b1 is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer. Br J Cancer. 2013;108(2):395\u2013401.","journal-title":"Br J Cancer"},{"issue":"9","key":"62_CR25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547\u201353.","journal-title":"J Clin Oncol"},{"issue":"11","key":"62_CR26","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10(11):1063\u20139.","journal-title":"Lancet Oncol"},{"key":"62_CR27","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Assessment report for Teysuno (tegafur, gimeracil, oteracil). 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001242\/wc500104417.pdf . Accessed 26 Mar 2013."},{"key":"62_CR28","doi-asserted-by":"crossref","unstructured":"Ajani JA, Rodriguez Pantigoso W, Bodoky G, et al. Non inferiority analysis of multicenter phase III comparing cisplatin\/S-1 (CS) with cisplatin\/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): methodology and results [abstract no. 668PD with poster]. European Society for Medical Oncology. 28 Sep\u20132 Oct 2012; Vienna.","DOI":"10.1016\/S0923-7534(20)33261-0"},{"key":"62_CR29","doi-asserted-by":"crossref","unstructured":"Bodoky G, Carrato A, Ravaioli A, et al. Quality of life in FLAGS trial: a randomized, phase III of Teysuno (S-1)\u00a0+\u00a0cisplatin (CS) compared to 5-FU\u00a0+\u00a0cisplatin (CF) in untreated advanced gastric cancer (AGC) patients [abstract no. 695P with poster]. European Society for Medical Oncology; Sep 28\u2013Oct 2 2012; Vienna.","DOI":"10.1016\/S0923-7534(20)33271-3"},{"key":"62_CR30","unstructured":"Asan Medical Center. Trial of 3-weekly versus 5-weekly schedule of S-1 plus cisplatin in gastric cancer (SOS). http:\/\/www.clinicaltrials.gov\/show\/NCT00915382 . Accessed 14 January 2013."},{"key":"62_CR31","unstructured":"Taiho Pharmaceutical Co., Ltd. Diffuse gastric and esophagogastric junction cancer S-1 trial (DIGEST). http:\/\/www.clinicaltrials.gov\/show\/NCT1285557 . Accessed 14 January 2013."},{"key":"62_CR32","unstructured":"US National Institutes of Health. ClinicalTrials.gov [online]. Accessed 14 January 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0062-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0062-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T07:46:31Z","timestamp":1595835991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0062-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,30]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0062-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,30]]}}}